戻る Agenda
Session 4: Global Phase 1
Session Chair(s)
Toshihiko Doi, MD, PHD
Deputy Director / Chief, Experimental Therapeutics, National Cancer Center Hospital East, Japan
Noboru Yamamoto, MD, PHD
Deputy Director, Department of Experimental Therapeutics, National Cancer Center Hospital, Japan
Speaker(s)
Johanna Bendell, MD
Chief Development Officer, Director, Drug Development Unit Nashville, Sarah Cannon, United States
Global Phase I Studies – Looking from Both Sides – the Academic and CRO Perspectives
Toshio Shimizu, MD, PHD
Professor, Department of New Experimental Therapeutics and Early Phase 1 Drug De, Kansai Medical University Hospital, Japan
First-in-Human Phase 1 Studies in Oncology: The New Challenge for Asian Investigational Sites
Satoshi Nishioka, MSC
Early Clinical Development Department, Group II, Daiichi Sankyo Co., Ltd., Japan
Experiences of Global Phase I Studies - Growth and Challenges -
Tomoko Takami
Director, Oncology Clinical Development, Oncology Science Unit, MSD K.K., Japan
Global Phase 1 from the Points of Japan Affiliate of US based Company